Try one of the below options to narrow down your search.
 |
Documents may be browsed by date, eg; Today, May, 2013.
Past years can be browsed too, eg; 2012, 2011, 2010, 2009 ...
Documents can be searched within a period by browsing to the date and then using the search form; or by direct links, eg; Media releases from 2013
Document tags (shown below the document date, eg; Schedule, SAForms, consultation ...) have highest priority when search results are ranked, followed by title, abstract and full text of document.
Parentheses and the keywords and, or and not have special meaning in search terms. And is implicit and can be omitted; or must be specified.
Remember to group or statements with parentheses if they are beside and statements.
Search examples
- consultation
- Search for consultations
- media and not antibiotics
- Search for media related documents that don't mention antibiotics.
- (media or consultation) and vaccines
- Search for media releases and consultation documents mentioning vaccinations.
Search term: consultation
2010
PHARMAC documents that matched your search:
Rationale for Draft CAC Terms of Reference
(12 pages, 155 KB)
2010/03/05
1 Introduction PHARMAC is reviewing the Terms of Reference (Terms of Reference) of our Consumer Advisory Committee (CAC). The review was required in Actioning Medicines New Zealand, the action plan accompanying the Government’s Medicines Strategy, Medicines New Zealand, and provides…
Proposal to widen access to fentanyl transdermal patches. Closed
(3 pages, 152 KB)
2010/03/04
4 March 2010 Proposal to widen access to fentanyl transdermal patches under a sole supply arrangement PHARMAC is seeking feedback on a proposal to list a new brand of fentanyl transdermal patches, Duropatch, as soon as possible (following Medsafe registration)…
Proposal to amend Growth Hormone access criteria. Closed
(2 pages, 150 KB)
2010/02/24
24 February 2010 Proposal to Amend Growth Hormone Access Criteria PHARMAC is seeking feedback on a proposal to make several amendments to the Growth Hormone Access Criteria. In summary, this proposal would result in: § a revision of the cut-off…
Proposal to widen access to gemcitabine hydrochloride and vinorelbine. Closed
(4 pages, 172 KB)
2010/02/19
19 February 2010 Proposal to widen access to gemcitabine hydrochloride and vinorelbine PHARMAC is seeking feedback on a proposal to widen funded access to gemcitabine hydrochloride. In summary, the proposal involves: § § Widening access to subsidised gemcitabine and vinorelbine…
Proposal to fund lignocaine urethral syringes. Closed
(1 page, 103 KB)
2010/02/17
17 February 2010 Proposal to fund lignocaine urethral syringes PHARMAC is seeking feedback on a proposal to list lignocaine gel 2% (10 ml urethral syringe) in Section B and in Part II of Section H of the Pharmaceutical Schedule from…
Proposal to fund bisacodyl suppositories (Dulcolax). Closed
(1 page, 105 KB)
2010/02/15
15 February 2010 Proposal to fund bisacodyl suppositories (Dulcolax) PHARMAC is seeking feedback on a proposal to fund a new brand of bisacodyl 10 mg suppositories (Dulcolax) and fully fund the 5 mg strength (Dulcolax) on the Pharmaceutical Schedule. This…
Proposal to reference price risperidone. Closed
(3 pages, 154 KB)
2010/02/15
15 February 2010 Proposal to apply reference pricing across different brands of risperidone PHARMAC is seeking feedback on a proposal to apply reference pricing across different brands of risperidone from 1 June 2010, where such reference pricing is possible in…
Proposal relating to provisional agreement with Allergan Australia Pty Ltd for various products. Closed
(3 pages, 160 KB)
2010/02/12
12 February 2010 Proposal relating to bimatoprost, brimonidine tartrate with timolol maleate and prednisolone actate PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Allergan Australia Pty Ltd for a number of products. In summary, this…
Proposal to fund ambrisentan (Volibris). Closed
(2 pages, 163 KB)
2010/01/29
29 January 2010 Proposal to fund ambrisentan (Volibris) for the treatment of pulmonary arterial hypertension PHARMAC is seeking feedback on a proposal to list ambrisentan (Volibris) in the Pharmaceutical Schedule for the treatment of pulmonary arterial hypertension. In summary, the…
Proposal to fund donepezil and decline memantine applications. Closed
(3 pages, 55 KB)
2010/01/27
27 January 2010 Proposal to fund donepezil hydrochloride and to decline funding for memantine hydrochloride PHARMAC is seeking feedback on a proposal to fund donepezil hydrochloride for the treatment of Alzheimer’s disease, subject to Special Authority restrictions (outlined on page…
